Phase I dose escalation trial of nintedanib in combination with pembrolizumab in patients with advanced solid tumors (PEMBIB trial)

被引：0

作者：

Baldini, C. ^{[1
]}

Danlos, F-X. ^{[2
]}

Varga, A. ^{[1
]}

Halse, H. ^{[3
]}

Mouraud, S. ^{[4
]}

Cassard, L. ^{[5
,6
]}

Bredel, D. ^{[4
]}

Escriou, G. ^{[4
]}

Parpaleix, A. ^{[7
]}

Rafie, S. ^{[1
]}

Abbassi, A. E. ^{[1
]}

Laghouati, S. ^{[8
]}

Farhane, S. ^{[1
]}

Tselikas, L. ^{[9
]}

Texier, M. ^{[10
]}

Adam, J. ^{[11
]}

Chaput, N. ^{[12
]}

Soria, J-C. ^{[13
]}

Massard, C. ^{[1
]}

Marabelle, A. ^{[14
]}

机构：

[1] Gustave Roussy, Drug Dev Dept, Villejuif, France

[2] Gustave Roussy, Drug Dev Dept, INSERM UMR1015, Villejuif, France

[3] Gustave Roussy, INSERM U1163, Imagine Inst, Villejuif, France

[4] Gustave Roussy, INSERM UMR1015, Villejuif, France

[5] Univ Paris Saclay, Gustave Roussy, Lab Immunomonitoring Oncol, CNRS UMS 3655, Villejuif, France

[6] Paris Saclay Univ, Gustave Roussy, INSERM US23, Villejuif, France

[7] Gustave Roussy, Serv Promot Etud Clin, Direct Rech Clin, Villejuif, France

[8] Gustave Roussy, Pharmacovigilance Dept, Villejuif, France

[9] Gustave Roussy Canc Campus, Intervent Radiol, Villejuif, France

[10] Gustave Roussy, Biostat, Villejuif, France

[11] Grp Hosp Paris St Joseph, Dept Pathol, Paris, France

[12] Univ Paris Saclay, UMR9019, Lab Immunomonitoring Oncol,CNRS, Gustave Roussy,Equipe Labellisee Ligue Natl Canc, Villejuif, France

[13] Inst Gustave Roussy, Direct Gen, Villejuif, France

[14] Inst Gustave Roussy, Drug Dev Dept, INSERM, UMR1015, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1368

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

984P

引用

页码：S842 / S843

页数：2